Chronic Hepatitis C Clinical Trial
Official title:
Hepatitis C Treatment in Underserved Populations
The purpose of this study is to examine the feasibility, safety, and effectiveness of treating persons who are actively using illicit drugs for hepatitis C using a collaborative, multidisciplinary, integrated care model. We hypothesize that by maximizing facilitators and minimizing barriers to treatment we can enable drug users to receive effective treatment for hepatitis C.
Status | Enrolling by invitation |
Enrollment | 30 |
Est. completion date | December 2020 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age 18 years or older - Used heroin, cocaine, or injected other drugs for at least 1 year - Have used heroin, cocaine and/or methamphetamine within the last 30 days - Test positive for HCV antibody - Are interested in being evaluated for HCV treatment Exclusion Criteria: - Persons who are obviously intoxicated, incoherent or otherwise unable to give informed consent are excluded from participation. Such persons may participate in the study if they return at a later date and are capable of providing informed consent. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Center for the Study of Hepatitis C, Weill Medical College, Cornell University | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Brian Edlin | State University of New York - Downstate Medical Center, Weill Medical College of Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sustained virologic response, defined as an undetectable serum HCV RNA level 24 weeks after completion of antiviral therapy. | SVR is measured 24 weeks after completion of antiviral treatment | 24 weeks after completion of antiviral treatment | No |
Secondary | completion of medical and psychiatric evaluation for antiviral therapy | Patients are expected to complete medical and psychiatric evaluation within 3-6 months but it may take longer in some cases. | No | |
Secondary | initiation of antiviral therapy | Patients are expected to initiate antiviral therapy (or decide not to) within 3-6 months but it may take longer in some cases. | No | |
Secondary | adherence to antiviral therapy | Adherence is measured weekly during the duration of prescribed antiviral therapy. (Antiviral therapy is prescribed for up to 48 weeks, depending on the patient's characteristics, the regimen, and the response to therapy.) | Weekly up to 48 weeks | No |
Secondary | completion of antiviral therapy | Completion is recorded at the time prescribed antiviral therapy is discontinued, whether that happens when the prescribed duration of therapy is complete or before. (Antiviral therapy is prescribed for up to 48 weeks, depending on the patient.) | No | |
Secondary | levels of alcohol and illicit drug use | Measured weekly during antiviral therapy and monthly before and after therapy for the duration of follow-up | Weekly up to 96 weeks | No |
Secondary | entry into treatment for substance use | Measured monthly from study enrollment through 24 weeks subsequent to completing prescribed course of antiviral therapy | Monthly up to 24 months | No |
Secondary | entry into treatment for another unaddressed medical or psychiatric condition | Measured monthly from study enrollment through 24 weeks subsequent to completing prescribed course of antiviral therapy | Monthly up to 24 months | No |
Secondary | neuropsychiatric side effects, including depression and hostility/irritability | Measured monthly during prescribed course of antiviral therapy and for 24 weeks thereafter | Monthly up to 72 weeks | Yes |
Secondary | treatment-limiting systemic, hematologic, or other side effects | Measured weekly during prescribed course of antiviral therapy and then monthly or quarterly thereafter (TSH, for example, is measured every 3 months during and after treatment) | Weekly up to 72 weeks | Yes |
Secondary | other adverse events or adverse effects | Measured monthly during prescribed course of antiviral therapy or as patients bring adverse events or effects to attention of physicians or study staff | Monthly up to 72 weeks | Yes |
Secondary | reinfection | Patients are monitored at 3-month intervals for reinfection. This will continue as long as possible after completion of antiviral therapy. | Quarterly up to 10 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
Completed |
NCT03673696 -
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT02250001 -
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
|
N/A | |
Completed |
NCT03088917 -
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
|
||
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT02865369 -
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
|
N/A | |
Recruiting |
NCT02638233 -
Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy
|
Phase 4 | |
Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
Completed |
NCT02788682 -
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy
|
N/A | |
Not yet recruiting |
NCT01949168 -
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
|
Phase 2 | |
Completed |
NCT01439776 -
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
|
Phase 4 | |
Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A | |
Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A | |
Terminated |
NCT00962936 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
|
Phase 1/Phase 2 | |
Completed |
NCT00968357 -
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
|
Phase 2 | |
Recruiting |
NCT01178749 -
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
|
N/A | |
Recruiting |
NCT00575627 -
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
|
Phase 4 | |
Completed |
NCT00537407 -
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
|
Phase 2 | |
Recruiting |
NCT00370617 -
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
|
Phase 4 | |
Completed |
NCT01684787 -
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
|
Phase 4 |